<HashMap><database>GEO</database><file_versions><headers><Content-Type>application/xml</Content-Type></headers><body><files><Csv>ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE312nnn/GSE312872/suppl/GSE312872_genome.csv.gz</Csv><Other>ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE312nnn/GSE312872/</Other></files><type>primary</type></body><statusCodeValue>200</statusCodeValue><statusCode>OK</statusCode></file_versions><scores/><additional><omics_type>Other</omics_type><species>Homo sapiens</species><gds_type>Other</gds_type><full_dataset_link>https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE312872</full_dataset_link><repository>GEO</repository><entry_type>GSE</entry_type></additional><is_claimable>false</is_claimable><name>Targeting DKC1-mediated pseudouridylation combined with PARPi induces synthetic lethality in HR-proficient tumors</name><description>Poly(ADP-ribose) polymerase inhibitors (PARPi) have revolutionized the treatment landscape of BRCA-mutant tumors by exploiting synthetic lethality arising from homologous recombination (HR) deficiency. Yet, a substantial proportion of solid tumors remain HR-proficient and thus less responsive to PARPi, underscoring the need to develop strategies that extend their therapeutic scope. Here, we uncover a previously unrecognized synthetic lethal interaction between PARPi and dyskerin (DKC1), an RNA pseudouridine synthase. By analyzing a publicly available genome-wide CRISPR-Cas9 screen conducted in the presence of niraparib, we identified DKC1 as a top candidate whose loss synergized with PARP inhibition to selectively kill HR-proficient cancer cells. Mechanistically, DKC1 depletion impaired pseudouridylation of chromatin-associated RNAs, particularly promoter-associated RNAs, resulting in reduced chromatin accessibility and compromised recruitment of DNA repair factors, including BRCA1 and RAD21. This chromatin remodeling phenocopies HR deficiency, rendering HR-proficient cells vulnerable to PARPi. Notably, co-targeting DKC1 and PARP elicited potent antitumor effects in vitro and in multiple HR-proficient xenograft models. These findings identify DKC1-mediated pseudouridylation as a critical determinant of chromatin structure and DNA repair fidelity, and extend the conceptual framework of synthetic lethality from genetic HR defects to epigenetic regulation, offering a promising strategy to broaden the clinical utility of PARPi.</description><dates><publication>2026/08/14</publication></dates><accession>GSE312872</accession><cross_references><GSM>GSM9356289</GSM><GSM>GSM9356288</GSM><GSM>GSM9356287</GSM><GSM>GSM9356286</GSM><GSM>GSM9356285</GSM><GSM>GSM9356284</GSM><GSM>GSM9356283</GSM><GSM>GSM9356282</GSM><GSM>GSM9356281</GSM><GSM>GSM9356280</GSM><GSM>GSM9356290</GSM><GSM>GSM9356279</GSM><GPL>24676</GPL><GSE>312872</GSE><taxon>Homo sapiens</taxon></cross_references></HashMap>